Cartesian Therapeutics
RNAC
68 hedge funds and large institutions have $60.9M invested in Cartesian Therapeutics in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 22 increasing their positions, 21 reducing their positions, and 4 closing their positions.
409% more call options, than puts
Call options by funds: $865K | Put options by funds: $170K
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
3% more funds holding
Funds holding: 66 → 68 (+2)
5% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 21
1.61% less ownership
Funds ownership: 24.66% → 23.05% (-1.6%)
8% less capital invested
Capital invested by funds: $66.5M → $60.9M (-$5.57M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$500K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$295K |
| 3 |
Millennium Management
New York
|
+$285K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$281K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$274K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$3.44M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$566K |
| 4 |
DFG
Delphi Financial Group
Wilmington,
Delaware
|
-$229K |
| 5 |
Renaissance Technologies
New York
|
-$203K |
RNAC Hedge Fund Activity: Q3 2025 in Review
68 of the 7,641 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q3 2025, worth a combined $60.9M — down 8.4% from $66.5M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new RNAC positions and 4 closed out — a net gain of 2 holders — while 22 added to existing stakes and 21 trimmed.
The largest buyer was GSA Capital Partners, adding an estimated $500K. The largest seller was MPM BioImpact, cutting an estimated $3.44M.
- 68 institutional investors held Cartesian Therapeutics (RNAC) as of Q3 2025, up from 66 in Q2 2025.
- Funds reported $60.9M of Cartesian Therapeutics stock for Q3 2025, down 8.4% quarter-over-quarter.
- 6 funds opened new Cartesian Therapeutics positions in Q3 2025 and 4 closed out, a net change of +2 holders.
- The largest Cartesian Therapeutics buyer in Q3 2025 was GSA Capital Partners, an estimated $500K added.
- The largest Cartesian Therapeutics seller in Q3 2025 was MPM BioImpact, an estimated $3.44M sold.
Based on aggregated 13F filings for Q3 2025.